Flagship launches Serif for modified DNA drugs

TL;DR

Serif Launches: Flagship Pioneering announced Serif Biomedicines, a Cambridge biotech developing modified DNA as a new class of medicines.[[1]](https://www.bizjournals.com/boston/news/2026/04/21/flagship-pioneering-launches-serif-dna-drug-method.html)[[2]](https://www.flagshippioneering.com/news/press-release/flagship-pioneering-launches-serif-biomedicines-to-establish-modified-dna-as-a-new-biotechnology)
$50M Funding: Flagship committed $50 million to advance the platform and initial drug programs after five years of development.[[1]](https://www.bizjournals.com/boston/news/2026/04/21/flagship-pioneering-launches-serif-dna-drug-method.html)
Preclinical Data: Upcoming presentation shows tolerability in primates and sustained gene expression with therapeutic effects after IV dosing.[[2]](https://www.flagshippioneering.com/news/press-release/flagship-pioneering-launches-serif-biomedicines-to-establish-modified-dna-as-a-new-biotechnology)[[3]](https://www.fiercebiotech.com/biotech/50m-flagship-pioneering-serif-hopes-write-new-chapter-dna-medicines)

The story at a glance

Flagship Pioneering launched Serif Biomedicines on April 21, 2026, to pioneer modified DNA medicines that combine strengths of mRNA and gene therapy while addressing their limits like immunogenicity and lack of redosability. Key figures include CEO Jacob Rubens and co-founder Noubar Afeyan of Flagship. The announcement coincides with plans to present preclinical data at a scientific meeting. This builds on Flagship's history of creating platforms like those behind Moderna.[[2]](https://www.flagshippioneering.com/news/press-release/flagship-pioneering-launches-serif-biomedicines-to-establish-modified-dna-as-a-new-biotechnology)[[4]](https://www.biopharmadive.com/news/serif-flagship-biotech-startup-modified-dna-mrna/817719)

Key points

Serif's modified DNA enables programmable, scalable, durable, and redosable gene expression inside cells without altering the genome.
Technology stack includes low-immunogenicity DNA, mRNA co-factors for nuclear entry, lipid nanoparticles for delivery, AI sequence design, and scalable manufacturing.[[2]](https://www.flagshippioneering.com/news/press-release/flagship-pioneering-launches-serif-biomedicines-to-establish-modified-dna-as-a-new-biotechnology)
Initial programs target rare diseases and immune programming.
Preclinical data to be presented: tolerability in non-human primates, durable gene expression, and therapeutic effects after intravenous administration.
Platform protected by over 20 patent families, including issued U.S. patents.
Founded in 2021 within Flagship Labs; team of about 50 employees.
Leadership: Jacob Rubens (CEO), Geoffrey von Maltzahn (board chair), Pete Smith (CSO).[[3]](https://www.fiercebiotech.com/biotech/50m-flagship-pioneering-serif-hopes-write-new-chapter-dna-medicines)

Details and context

Serif reshapes DNA's structure and chemistry to overcome barriers like immune response and poor nuclear access that have limited DNA therapeutics beyond gene therapy. The approach uses circular DNA (single- and double-stranded versions) with chemical modifications, packaged in lipid nanoparticles alongside mRNA that produces proteins to shuttle DNA into the nucleus.[[3]](https://www.fiercebiotech.com/biotech/50m-flagship-pioneering-serif-hopes-write-new-chapter-dna-medicines)

Unlike transient RNA therapies, non-redosable gene therapies using viruses, or integrating genome editors, modified DNA aims for a safer profile with repeat dosing and broad tissue targeting. Flagship, known for originating companies like Moderna (mRNA) and Generate Biomedicines (proteins), sees this as the next layer in biology's central dogma.[[2]](https://www.flagshippioneering.com/news/press-release/flagship-pioneering-launches-serif-biomedicines-to-establish-modified-dna-as-a-new-biotechnology)

The company plans partnerships alongside owned programs, drawing from successes like Alnylam, whose ex-CEO John Maraganore advises Serif.

Key quotes

“When a foundational layer of biology becomes engineerable, new therapeutic categories are born that can redefine the possibilities for medicine,” said Noubar Afeyan, Ph.D., founder and CEO of Flagship Pioneering and co-founder of Serif Biomedicines.[[2]](https://www.flagshippioneering.com/news/press-release/flagship-pioneering-launches-serif-biomedicines-to-establish-modified-dna-as-a-new-biotechnology)

“More than 75 years after DNA was recognized as the key information molecule in biology, turning DNA into a reliable medicine remains one of our industry’s biggest opportunities,” said Jacob Rubens, Ph.D., co-founder and CEO of Serif Biomedicines.[[2]](https://www.flagshippioneering.com/news/press-release/flagship-pioneering-launches-serif-biomedicines-to-establish-modified-dna-as-a-new-biotechnology)

Why it matters

Modified DNA could expand genetic medicines to more diseases by offering durable effects without viral risks or single-use limits, potentially lowering costs and broadening access. For biotech investors and firms, it signals Flagship's continued push into programmable biology platforms amid funding challenges for cell/gene therapies. Watch the upcoming preclinical data presentation and early partnership announcements, though timelines depend on scientific feedback.[[3]](https://www.fiercebiotech.com/biotech/50m-flagship-pioneering-serif-hopes-write-new-chapter-dna-medicines)

What changed

Serif operated in stealth since 2021 with platform development; now publicly launched April 21, 2026, with $50 million committed and preclinical data ready for presentation.

FAQ

Q: What makes Serif's modified DNA different from mRNA or gene therapy?

A: It combines mRNA's programmability and gene therapy's durability but avoids transient effects, immune issues from viruses, and non-redosability by using non-viral lipid nanoparticles, chemical tweaks, and mRNA co-factors for nuclear entry without genome changes.[[2]](https://www.flagshippioneering.com/news/press-release/flagship-pioneering-launches-serif-biomedicines-to-establish-modified-dna-as-a-new-biotechnology)

Q: What preclinical results will Serif present?

A: Data from non-human primate studies show tolerability after IV dosing, plus sustained gene expression with functional and therapeutic effects in models.[[2]](https://www.flagshippioneering.com/news/press-release/flagship-pioneering-launches-serif-biomedicines-to-establish-modified-dna-as-a-new-biotechnology)

Q: What are Serif's initial focus areas?

A: Drug discovery programs target rare diseases and immune programming, where the platform's properties like redosability offer advantages.[[4]](https://www.biopharmadive.com/news/serif-flagship-biotech-startup-modified-dna-mrna/817719)

Q: Who leads Serif Biomedicines?

A: Jacob Rubens, Ph.D., is co-founder and CEO; co-founders include Noubar Afeyan and Flagship partners; board chair is Geoffrey von Maltzahn.[[2]](https://www.flagshippioneering.com/news/press-release/flagship-pioneering-launches-serif-biomedicines-to-establish-modified-dna-as-a-new-biotechnology)